Se afișează postările cu eticheta Approach. Afișați toate postările
Se afișează postările cu eticheta Approach. Afișați toate postările

joi, 15 decembrie 2011

Using A Restrictive Approach In Post-Surgical Blood Transfusions Is Safe And Saves Blood

Main Category: Transplants / Organ Donations
Also Included In: Blood / Hematology
Article Date: 15 Dec 2011 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
New research published online in advance of print in the New England Journal of Medicine could refine the way that post-operative patients are cared for while preserving blood supply levels, an essential resource that is difficult to maintain at necessary quantities throughout the year. The study, led by researchers at UMDNJ-Robert Wood Johnson Medical School, shows that using a liberal blood transfusion strategy in post-operative hip-surgery patients did not appear to improve patients' recoveries or reduce the rate of death, suggesting therefore, that utilizing a restrictive transfusion approach would be appropriate patient care and conserve blood.

"The need for, and the quantity of, transfusion of red blood cells in post-operative patients is controversial, but has not previously been evaluated in a large study," said Jeffrey L. Carson, MD, the Richard C. Reynolds Professor of Medicine and study chair of the Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair, known as the FOCUS trial. "Our research shows that using a more restrictive transfusion approach could become the standard of care for post-orthopedic surgical, high-risk patients with underlying cardiovascular disease and save blood a precious resource."

The study examined more than 2,000 high-risk patients, with a mean age of 82, with underlying cardiovascular disease or risk factors, and hemoglobin levels below 10 grams per deciliter, after hip surgery. Hemoglobin (Hb or Hgb) is the main component of red blood cells that carries oxygen throughout the body and is normally greater than 12 to 13 grams per deciliter. Patients commonly have a low hemoglobin level after surgery that results from bleeding and often receive red blood cell transfusion as treatment. However, the optimal level of hemoglobin at which blood transfusion should be administered has been unknown.

"This clinical trial is unique in that all patients were considered very high risk due to age and prior history of cardiovascular disease, including myocardial infarction (heart attack), or risk factors for heart disease," said Dr. Carson.

Patients were randomly assigned a liberal transfusion strategy (transfusion if hemoglobin was less than 10 grams per deciliter) or a restrictive transfusion strategy (transfusion if hemoglobin was less than 8 grams per deciliter). Patients in the restrictive group also received a transfusion if they exhibited symptoms of anemia including chest pain, congestive heart failure or unexplained excessive heart rate. At 30 and 60 days post-surgery, there was no difference between the groups in the patients' inability to walk without assistance nor was there a significant difference in the rate of death or heart attacks. Because the liberal transfusion strategy did not provide a benefit to patient outcomes as compared with the restrictive strategy, the study suggests that less blood transfusion may be appropriate and does not detrimentally affect patients' recovery after surgery.

The FOCUS Trial was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health. The study results, "Liberal or Restrictive Transfusion in High-risk Patients after Hip Surgery", were published online today. Dr. Carson's team of researchers at Robert Wood Johnson Medical School included: Helaine Noveck, MPH, deputy director, Clinical Coordinating Center; George G. Rhoads, MD, MPH, interim dean and professor at UMDNJ-School of Public Health; and Karen Dragert, RN, lead research nurse. He was assisted by investigators at the University of Maryland School of Medicine (Michael L. Terrin, MD, MPH, principal investigator, Data Coordinating Center, and Jay Magaziner, PhD, MSHyg) and from 47 hospitals in the United States and Canada.

Article adapted by Medical News Today from original press release. Source: Springer Science+Business Media
Visit our transplants / organ donations section for the latest news on this subject. Springer Science+Business Media Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Robert Wood Johnson Medical School. "Using A Restrictive Approach In Post-Surgical Blood Transfusions Is Safe And Saves Blood." Medical News Today. MediLexicon, Intl., 15 Dec. 2011. Web.
15 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Malaria In Africa - A Logistics Approach

Main Category: Tropical Diseases
Also Included In: Public Health
Article Date: 15 Dec 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
The problems of archaic logistics infrastructure, inefficient distribution channels and disruptive black markets must all be addressed urgently if Africa is to cope with the growing problem of malaria, according to a study published in the International Journal of Logistics Systems and Management.

Historically, malaria is humanity's biggest killer and although it has been eradicated in some regions it remains the biggest infectious threat in many parts of the world. Malaria kills 1.1 million people every year and afflicts 300 million with acute illness. The vast majority of those infected are children under the age of five years. Getting anti-malarial drugs to those at risk across Africa is an enormous problem of economics, politics and infrastructure. Now, Hokey Min of the College of Business Administration, at Bowling Green State University, in Ohio, has identified the various factors that must be considered if this situation is to be remedied.

Min has developed a comprehensive supply chain map that reveals the labyrinths of African logistics infrastructure, distribution channels, government regulations and business customs. This map could help improve access to anti-malarial drugs as well as avoiding disruption to the drug supply chain. He points out that there are countless challenges posed by trade and regulatory barriers across Africa. Communication difficulties, seasonal variations in logistics infrastructure and a high rate of theft and damage during storage and transit also potentially overwhelm any company hoping to distribute anti-malarial drugs in the African market. He suggests that outsourcing of logistics functions to control such risks and costs might be the only solution.

Moreover, African legal and ethical codes have many "subtleties" he says, so it is potentially beneficial to find local partners that can assist with such subtleties. In addition, the chronically poor roads suggest that local transport options, such as donkey carts and bicycles should also be considered as viable modes of distribution rather than a company expecting to transport antimalarials to rural areas in trucks.

Recognizing the idiosyncrasies of drug distribution in Africa is essential to coping with the lethal problem of malaria. "Supply chain efficiency for distribution of anti-malarial drugs is a matter of life and death to many malaria-endemic countries in Africa," says Min. And, although few attempts have been made to tackle the problem, an understanding of the African distribution system and the unique but complicated socioeconomic and regulatory environments affecting African logistics operations is essential. Min's preliminary study on addressing the issues points the way forward to improving a disheartening situation.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our tropical diseases section for the latest news on this subject. "Mapping the supply chain of anti-malarial drugs in Sub-Saharan African countries" in Int. J. Logistics Systems and Management, 2012, 11, 1-23
Inderscience Publishers Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Inderscience Publishers. "Malaria In Africa - A Logistics Approach." Medical News Today. MediLexicon, Intl., 15 Dec. 2011. Web.
15 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

New Approach To Stem Cell Transplants Redirects Lymphocytes From Harming Vital Organs, Without Dangers Of Immunosuppression

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Stem Cell Research;  Transplants / Organ Donations;  HIV / AIDS
Article Date: 15 Dec 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that was presented at the 53rd American Society of Hematology Annual Meeting. Standard GvHD treatments suppress the immune system, reducing - but not eliminating - the risk of developing the common problem. In the current trial, treatment with the HIV drug maraviroc dramatically reduced the incidence of GvHD in organs where it is most dangerous - without compromising the immune system and leaving patients more vulnerable to severe infections.

"There hasn't been a change to the standard of care for GvHD since the late 1980s, so we're very excited about these results, which exceeded our expectations," says Ran Reshef, MD, an assistant professor in the division of Hematology-Oncology and a member of the Hematologic Malignancies Research Program at Penn's Abramson Cancer Center. "Until now, we thought that only extreme suppression of the immune system can get rid of GvHD, but in this approach we are not killing immune cells or suppressing their activity, we are just preventing them from moving into certain sensitive organs that they could harm."

Reshef and colleagues will present results showing that maraviroc is safe and feasible in ASCT patients - those who receive stem cells from a healthy donor - and that a brief course of the drug led to a 73 percent reduction in severe GvHD in the first six months after transplant, compared with a matched control group treated at Penn during the same time period (6 percent developed severe GvHD vs. 22 percent, respectively).

"Just like in real estate, immune responses are all about location, location, location," Reshef says. "Cells of the immune system don't move around the body in a random way. There is a very distinct and well orchestrated process whereby cells express particular receptors on their surface that allow them to respond to small proteins called chemokines. The chemokines direct the immune cells to specific organs, where they are needed, or in the case of GvHD, to where they cause damage."

Thirty-eight patients with blood cancers, including acute myeloid leukemia, myelodysplastic syndrome, lymphoma, myelofibrosis, and others, enrolled in the phase I/II trial. All patients received the standard GvHD prevention drugs tacrolimus and methotrexate, plus a 33-day course of maraviroc that began two days before transplant. In the first 100 days after transplant, none of the patients treated with maraviroc developed GvHD in the gut or liver. By contrast, 12.5 percent of patients in the control group developed GvHD in the gut and 8.3 percent developed it in the liver within 100 days of their transplant.

The differential impact of maraviroc on those organs indicates that the drug is working as expected, by limiting the movement of T lymphocytes to specific organs in the body. Maraviroc works by blocking the CCR5 receptor on lymphocytes, preventing the cells from trafficking to certain organs. The researchers saw no effect on skin GvHD, so they theorize that the CCR5 receptor might be more important for sending lymphocytes into the liver and the gut than for the skin.

After 180 days, the benefit of maraviroc appeared to be partially sustained in patients and the cumulative incidence of gut and liver GvHD rose only to 8.8 percent and 2.9 percent, respectively. The cumulative incidence in the control group, however, remained higher, at 28.4 percent for gut and 14.8 percent for liver GvHD. Based on those data, the research team plans to try a longer treatment regimen with maraviroc to see if they could prolong the protective effect.

Maraviroc treatment did not appear to increase treatment-related toxicities in these patients, nor did it alter the relapse rate of their underlying disease.

David Porter, MD, professor of Medicine and director of Blood and Marrow Transplantation in the Abramson Cancer Center, and Robert Vonderheide, MD, DPhil, associate professor of Medicine and Associate Director for Translational Research at the Abramson Cancer Center, are the senior authors of the study.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our lymphoma / leukemia / myeloma section for the latest news on this subject. Funding support for this investigator-initiated trial comes from Pfizer, the makers of maraviroc, the Leukemia and Lymphoma Society, the American Society of Hematology, and the National Institutes of Health (K24-CA117879).
The findings were presented December 13, in the Manchester Grand Hyatt San Diego's Douglas Pavilion A.
Abstract #1011: Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist - Final Results of a Phase I/II Study

University of Pennsylvania School of Medicine

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Pennsylvania School of Medicine. "New Approach To Stem Cell Transplants Redirects Lymphocytes From Harming Vital Organs, Without Dangers Of Immunosuppression." Medical News Today. MediLexicon, Intl., 15 Dec. 2011. Web.
15 Dec. 2011. APA
University of Pennsylvania School of Medicine. (2011, December 15). "New Approach To Stem Cell Transplants Redirects Lymphocytes From Harming Vital Organs, Without Dangers Of Immunosuppression." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/239166.php.

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here